George Carrum

3.0k total citations · 1 hit paper
53 papers, 1.6k citations indexed

About

George Carrum is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, George Carrum has authored 53 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 18 papers in Immunology and 16 papers in Pathology and Forensic Medicine. Recurrent topics in George Carrum's work include CAR-T cell therapy research (13 papers), Lymphoma Diagnosis and Treatment (13 papers) and Hematopoietic Stem Cell Transplantation (11 papers). George Carrum is often cited by papers focused on CAR-T cell therapy research (13 papers), Lymphoma Diagnosis and Treatment (13 papers) and Hematopoietic Stem Cell Transplantation (11 papers). George Carrum collaborates with scholars based in United States, France and Australia. George Carrum's co-authors include Helen E. Heslop, Malcolm K. Brenner, Catherine M. Bollard, Adrian P. Gee, Cliona M. Rooney, Stephen Gottschalk, Meng‐Fen Wu, M. Helen Huls, Karin Straathof and Uday Popat and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

George Carrum

49 papers receiving 1.6k citations

Hit Papers

Sustained Complete Responses in Patients With Lymphoma Re... 2013 2026 2017 2021 2013 100 200 300

Peers

George Carrum
HE Heslop United States
M. Lia Palomba United States
GJ Freeman United States
Elise A. Chong United States
HE Heslop United States
George Carrum
Citations per year, relative to George Carrum George Carrum (= 1×) peers HE Heslop

Countries citing papers authored by George Carrum

Since Specialization
Citations

This map shows the geographic impact of George Carrum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George Carrum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George Carrum more than expected).

Fields of papers citing papers by George Carrum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George Carrum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George Carrum. The network helps show where George Carrum may publish in the future.

Co-authorship network of co-authors of George Carrum

This figure shows the co-authorship network connecting the top 25 collaborators of George Carrum. A scholar is included among the top collaborators of George Carrum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George Carrum. George Carrum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ramos, Carlos A., Amy N. Courtney, Premal Lulla, et al.. (2024). Off-the-Shelf CD19-Specific CAR-NKT Cells in Patients with Relapsed or Refractory B-Cell Malignancies. Transplantation and Cellular Therapy. 30(2). S41–S42. 15 indexed citations
2.
3.
Ramos, Carlos A., Amy N. Courtney, Simon N. Robinson, et al.. (2022). Allogeneic NKT Cells Expressing a CD19-Specific CAR in Patients with Relapsed or Refractory B-Cell Malignancies. Transplantation and Cellular Therapy. 28(3). S54–S54. 4 indexed citations
4.
Friend, Brian D., Ibrahim N. Muhsen, Shreeya Patel, et al.. (2022). Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplantation. 57(4). 579–585. 1 indexed citations
5.
Vasileiou, Spyridoula, LaQuisa Hill, Manik Kuvalekar, et al.. (2022). Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 108(7). 1840–1850. 16 indexed citations
6.
Ramos, Carlos A., Amy N. Courtney, Simon N. Robinson, et al.. (2021). Allogeneic NKT Cells Expressing a CD19-Specific CAR in Patients with Relapsed or Refractory B-Cell Malignancies: An Interim Analysis. Blood. 138(Supplement 1). 2819–2819. 28 indexed citations
7.
Epperla, Narendranath, Namrata Shah, George Carrum, et al.. (2017). Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. Clinical Lymphoma Myeloma & Leukemia. 17(7). 408–414. 8 indexed citations
8.
Perna, Serena, Stephen Gottschalk, Vicky Torrano, et al.. (2015). Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Lymphoma Post Allogeneic Stem Cell Transplant. Biology of Blood and Marrow Transplantation. 21(2). S148–S148. 2 indexed citations
9.
Sung, Anthony D., Daniel Grima, Lisa Bernard, et al.. (2013). Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. Bone Marrow Transplantation. 48(11). 1444–1449. 23 indexed citations
10.
Campos, Susana M., Jian Wu, Carlos A. Ramos, et al.. (2013). Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplantation. 49(2). 219–222. 5 indexed citations
11.
Sandmaier, Brenda M., Helen E. Heslop, Uday Popat, et al.. (2011). Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60–78 years of age. British Journal of Haematology. 153(1). 76–82. 31 indexed citations
12.
Heslop, H E, Malcolm K. Brenner, George Carrum, et al.. (2010). Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leukemia & lymphoma. 51(4). 664–670. 18 indexed citations
13.
Foster, Aaron E., Fatma Visal Okur, Ettore Biagi, et al.. (2009). Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Molecular Cancer. 8(1). 106–106. 4 indexed citations
14.
Kamble, Rammurti T., Cheng‐Chang Chang, Sergio Sánchez, & George Carrum. (2006). Central nervous system graft-versus-host disease: report of two cases and literature review. Bone Marrow Transplantation. 39(1). 49–52. 50 indexed citations
15.
Popat, Uday, Helen E. Heslop, April Durett, et al.. (2006). Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplantation. 37(6). 547–552. 13 indexed citations
16.
Kennedy‐Nasser, Alana A., Kathryn Leung, Anita Mahajan, et al.. (2006). Comparable Outcomes of Matched-Related and Alternative Donor Stem Cell Transplantation for Pediatric Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation. 12(12). 1277–1284. 78 indexed citations
17.
18.
Bachier, Carlos, Paul Shaughnessy, Donna A. Wall, et al.. (2004). Valganciclovir for the Early Prophylaxis of Cytomegalovirus (CMV) Infection after Allogeneic Stem Cell Transplantation.. Blood. 104(11). 5074–5074. 1 indexed citations
19.
Bollard, Catherine M., Laura K. Aguilar, Karin Straathof, et al.. (2004). Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease. The Journal of Experimental Medicine. 200(12). 1623–1633. 285 indexed citations
20.
Popat, Uday, George Carrum, & Helen E. Heslop. (2003). Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treatment Reviews. 29(1). 3–10. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026